<DOC>
	<DOC>NCT02873286</DOC>
	<brief_summary>A total of 400 subjects will be recruited into five treatment subject groups à 80 subjects.Subject will receive two administrations 4 weeks apart which will consist of MVA-BN-RSV Dose 1, MVA-BN-RSV Dose 2 or Placebo (TBS).</brief_summary>
	<brief_title>RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>signed and dated an informed consent form and HIPAA. Subjects without symptomatic cardiopulmonary and/or metabolic disease. Body mass index (BMI) ≥ 18.5 and ≤ 39.9. Negative human immunodeficiency virus antibody test (antiHIV), HBsAG and HCV virus. Electrocardiogram (ECG) without clinically significant acute findings. WOCBP must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to each vaccination. pregnant or breastfeeding women. History or current clinical manifestation of any serious medical condition. History of or active autoimmune disease. Known or suspected impairment of immunologic functions including, but not limited to chronic inflammatory bowel disorders, diabetes mellitus type I. Knowledge/history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. History of anaphylaxis or severe allergic reaction to any vaccine. Chronic systemic administration defined as more than 14 days of &gt; 5 mg prednisone per day.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>RSV Vaccines</keyword>
	<keyword>Respiratory Syncytial Virus Vaccines</keyword>
</DOC>